HomeAI · summaries
Storia in 2 fonti
FDA hits Lundbeck with untitled letter over efficacy claims on migraine drug Vyepti
Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy clai | The FDA took issue with multiple claims describing Vyepti's efficacy listed on Lundbeck's healthcare provider webpage for the drug.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
FDA hits Lundbeck with untitled letter over efficacy claims on migraine drug Vyepti
Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially…
- ·
endpoints.news
FDA criticizes Lundbeck for now-deleted webpages promoting its migraine treatment
The FDA slams Lundbeck for now-deleted Vyepti webpages claiming